



**DamanshourUniversity**  
**Faculty of Pharmacy**

**جامعة دمنهور**  
**كلية الصيدلة**



# **Curriculum Vitae**

**Maged Wasfy Helmy Wisa, Ph.D.**

**Professor of**  
**Pharmacology and Toxicology**

Department of Pharmacology and Toxicology  
Faculty of Pharmacy  
Damanshour University  
Egypt

October 2020



**Damanhour University**  
**Faculty of Pharmacy**

جامعة دمنهور  
كلية الصيدلة



## **Maged Wasfy Helmy Wisa**

**Damanhour University**  
**Faculty of Pharmacy**  
**Department of Pharmacology and Toxicology**  
**El-Gomhoriast., Damanhour, El-Bhaira, Egypt.**  
**Mobile: (+2) 0122 3461 575**

**e-mail: [maged.helmy@pharm.dmu.edu.eg](mailto:maged.helmy@pharm.dmu.edu.eg)**

**[magedwhw@yahoo.com](mailto:magedwhw@yahoo.com)**

**[maged.helmy@adj.aast.edu](mailto:maged.helmy@adj.aast.edu)**

**[magedwhw88@gmail.com](mailto:magedwhw88@gmail.com)**



### **Personal information:**

**Date of birth:** August 5<sup>th</sup>, 1975

**Nationality:** Egyptian

**Current positions:**

- Acting Vice Dean of Postgraduate Studies and Researches
- Professor of Pharmacology & Toxicology, Faculty of Pharmacy, Damanhour University, Egypt.
- Clinical Pharmacy Program Coordinator, Faculty of Pharmacy, Damanhour University, Egypt.
- Member of *Postgraduate Studies and Researches Committee*, Damanhour University.
- Member of *Projects' Management Committee*, Damanhour University.
- Running Pharm D degree candidate (2<sup>nd</sup> Semester), Faculty of Pharmacy, Alexandria University

**Languages:** Fluent Arabic and English (written & spoken)

### **Education:**

- 1. Doctor of Philosophy in Pharmaceutical sciences (Pharmacology)** Faculty of Pharmacy, Alexandria University, Egypt (**October 2009**), "**Evaluation of the anti-carcinogenic actions of drugs with a possible novel targets for treatment of experimentally induced breast cancer in rats**"
- 2. Master Degree in Pharmaceutical sciences (Pharmacology)** Faculty of Pharmacy, Alexandria University, Egypt (**January 2005**), "**The Effect of Anastrozole and / or Celecoxib on 7, 12-dimethylbenzanthracene induced rat mammary tumors**"



**3. Bachelor degree of pharmaceutical sciences, Faculty of pharmacy, Alexandria University, Egypt (June 1997).**

### **Employment History& Positions held:**

#### **1. Faculty of Pharmacy, Damanhour University, Egypt (9/2014 till now)**

- **Acting Vice Dean of Postgraduate Studies and Researches**, since 27/7/2017 till now
- **Professor of Pharmacology & Toxicology**, since 30/9/2020 till now.
- **Assistant Professor of Pharmacology & Toxicology**, since 30/9/2015 till 29/9/2020.
- **Lecturer of Pharmacology**, Department pharmacology& Toxicology, since 17/9/2014 till 29/9/2015.
- **Clinical Pharmacy Program Coordinator**, Faculty of Pharmacy, Damanhour University, Egypt, from 10/2014 till now.
- Member of **Quality Assurance Unit**, Faculty of Pharmacy, Damanhour University, Egypt, from 10/2014 till 9/2018. Now I am a member in the **Committee of Faculty Self-Assessment for Academic Accreditation**(Strategic Plane sector & Postgraduates Studies Sector)

#### **2. Damanhour University, Egypt (9/2014 to now)**

- Member of **Postgraduate Studies and Researches Committee**, Damanhour University, from 8/2017 till now
- Member of **Projects' Management Committee**, Damanhour University from 19/11/2018
- Member of **International Publications and Scientific Conferences Committee**, Damanhour University

#### **3. Faculty of Pharmacy & Drug Manufacturing, Pharos University in Alexandria (PUA), Egypt (2007-2014)**

- Lecturer of Pharmacology, Department pharmacology & Toxicology, from 26/10 /2009 till 31/8/2014.
- Executive Manager of Quality Assurance Unit, Faculty of Pharmacy & Drug Manufacturing, PUA, from 5 / 2011 till 31/8/2014.
- Member of PUA Continuous Professional Development Team, PUA Educational Development Center, from 10 / 2012.
- Assistant Lecturer of Pharmacology, Department pharmacology & Toxicology, from 1/1/2007–25/11/ 2009

#### **4. Faculty of Pharmacy, October 6 University, Egypt (2000-2006)**

- Assistant Lecturer of Pharmacology, Department pharmacology & Toxicology, from 1 / 2005 – 8 / 2006.



- Demonstrator of Pharmacology, Department pharmacology & Toxicology, from 6/ 2000 – 1 / 2005

## **Teaching Experiences:**

### **A. Damanhour University (2014-2020)**

**A.1.** Participation in teaching the following **Undergraduate students'** courses in the Department of Pharmacology and Toxicology, Faculty of Pharmacy, Damanhour University, Egypt including:

1. Pharmacology I, II (3rd year students)
2. Clinical Pharmacology (4<sup>th</sup> year students)
3. Toxicology & First Aid (4<sup>th</sup> year students)
4. Drug Interactions (5<sup>th</sup> year students)
5. Pharmacotherapeutics I, II (5<sup>th</sup> year students, Clinical Pharmacy Program)
6. Biophysics (1st year students of clinical pharmacy program 2014 - 2019)

**A.2.** Teach Pharmacology related **Postgraduate courses**, Faculty of Pharmacy, Damanhour University, Egypt including:

1. Advanced topics in Pharmacology (Master & Doctoral Degree)
2. Advanced topics in Toxicology (Master & Doctoral Degree)
3. Immunopharmacology (Master & Doctoral Degree)
4. Pharmacology of special populations
5. Cancer Biology (Master & Doctoral Degree)
6. Pharmacotherapeutics I (Clinical Pharmacy Diploma Degree)
7. Pharmacotherapeutics II (Clinical Pharmacy Diploma Degree)
8. Pharmacotherapeutics III (Clinical Pharmacy Diploma Degree)

**A.3.** Teach Pharmacology course for 1st year students of **Faculty of Nursing**, Damanhour University, Egypt as a main lecturer and Course coordinator. (**Academic year 2014-2015**)

### **B. Faculty of Pharmacy and Drug Manufacturing, Pharos University in Alexandria (2007-2014)**

**B.1.** Participation in teaching the following Undergraduate students' courses in the Department of Pharmacology and Toxicology, Faculty of Pharmacy & Drug Manufacturing, Pharos University, Egypt as a lecturer (2009-2014):

1. Basic Pharmacology I (Junior students)
2. Basic Pharmacology II (Mid-senior students)
3. Forensic Chemistry (Mid-senior students)
4. Pharmacotherapeutics (Senior students)
5. Bioevaluation & Drug Screening (Senior students)
6. Geriatric Pharmacy (Elective course for Senior & Mid-senior students)
7. Nutrition (Elective course for Senior & Mid-senior students)
8. Graduation Projects (Senior students)
9. In-house part of Summer Training (Junior & Mid-senior students)

➤ For all of these courses, beside my participation in teaching lectures, I participate in:



- a) Designing and supervising practical parts and/or tutorials (if any)
- b) Designing and marking of written exams & oral exams (if any)
- c) Preparing of course specification, matrix and reports
- d) Preparing course portfolio

**B.2.** Participation in preparing and teaching the practical sessions of the following Undergraduate students' courses in the Department of Pharmacology and Toxicology, Faculty of Pharmacy & Drug Manufacturing, Pharos University, Egypt as an assistant lecturer (2007-2009):

1. Cell Biology (Freshmen students)
2. Anatomy & Histology (Freshmen students)
3. Physiology I & II (Sophomore students)
4. Biochemistry I & II (Junior students)
5. Basic Pharmacology I (Junior students)
- Basic Pharmacology II (Mid-senior students)

**C. Faculty of Pharmacy October 6 University, Giza, Egypt (2000-2006)**

Participation in preparing and teaching the practical sessions of the following Undergraduate students' courses in the Department of Pharmacology and Toxicology, Faculty of Pharmacy, October 6 University, Egypt as a demonstrator (2000-2005) and as an assistant lecturer (2005-2006):

1. Pharmacology ( part 1, 2 and 3)
2. Clinical Pharmacology and Applied therapeutics
3. Clinical Pharmacy
4. Biological Standardization and Screening of drug
5. Toxicology and Forensic Chemistry

**Academic Experiences:**

**A. Damanhour University (2014/2015)**

**A.1.** Participate, as an **Acting Vic-Dean of Postgraduate Studies and Researches**, in the following activities:

1. Attendance of all meeting of Postgraduate Studies and Researches committee taking administrative decisions concerning the program
2. Design study plane
3. Coordination between Faculty staff members implicated in teaching of the program
4. Organization of Final Exams

**A.2.** Participate, as **Clinical Pharmacy Program Coordinator**, in the following activities:



5. Attendance of all meeting of Clinical Pharmacy Program's Higher committee & Clinical Pharmacy Program's Executive committee, taking administrative decisions concerning the program
6. Design study plane
7. Coordination between Faculty staff members implicated in teaching of the program
8. Organization of Final Exams

**A.3.** Participate, as a member of Quality Assurance Unit, in the following activities:

1. Preparation and revision of courses specifications & matrices of all courses of B.Sc. Program.
2. Participate in preparation of the project proposal of the 1<sup>st</sup> call of SDEE "Support and Development of Educational Effectiveness in Higher Education Institutions" offered by Egyptian Ministry of Higher Education
3. Acting as Deputy Executive Director of the SDEE project offered by Egyptian Ministry of Higher Education (April 2015-December 2016)
4. **Participate in Committee of Faculty Self-Assessment for Academic Accreditation** (Strategic Plane sector & Postgraduates Studies Sector)
5. **Participate as a Lecturer** in several workshops for Quality Assurance Unit in Faculty of Pharmacy:
  - a) "Understanding of Course Specification" 22/11/2014 and repeated
  - b) "Analysis of Students' Achievements Results and Writing Course Reports" 26/10/2015
  - c) "Basics of Quality Assurance in Academic Learning" 12/5/2016
  - d) "Preparation for Faculty Self-Assessment for Academic Accreditation" 21/12/2016
  - e) "Preparing of Strategic Plan of Faculty of Pharmacy, Damanhour University, Brain Storming & SWOT Analysis" 10/2/2017.

**A.3. Memberships in Faculty Committees:**

1. Member in the **Department of Pharmacology & Toxicology Council** (9/2014 till now)
2. Member in the **Quality Assurance Unit**(10/2014 till 9/2018)
3. Member of **Clinical Pharmacy Program's Higher committee** (10/2014 till now)
4. Member of **Clinical Pharmacy Program's Executive committee** (10/2014 till now)

**B. Faculty of Pharmacy and Drug Manufacturing, Pharos University in Alexandria (2007-2014)**



**B.1.** Acting as an *Executive Manager of Quality Assurance Unit*, Faculty of Pharmacy & Drug Manufacturing, Pharos University, Egypt, from 5 / 2011 till 31/8/2014. I supervise and participate in the following activities:

1. Preparation and revision of the final Self-Study proposal (2012-2013) for accreditation from National Authority for Quality Assurance and Accreditation of Higher Education (NAQAEE)
2. Design, preparation and revision of
  - a) Faculty Strategic plan (2012-2017)
  - b) Faculty Mission, Vision and Objectives, final modification (2014)
  - c) Faculty Code of ethics & Ethics of scientific research (2013)
  - d) Faculty Scientific Research Plan (2014)
  - e) B.Sc. Program Specification, Matrix and Report.
  - f) Faculty Teaching & Learning Strategies
  - g) Faculty Annual Reports (2011-2014)
  - h) Cross-matching Studies of Courses, Program ILOs and National Academic Reference Standards (NAARS)
3. Organize & Participate in all activities aimed to clarify and declare all aspects and requirements of Quality Assurance between all faculty staff members, students, laboratory technicians and employees.
4. Communicate with faculty stakeholders

**B.2.** Acting as a member of PUA Educational Development Center team, from 10 / 2012 till now, I am responsible for teaching two modules of PUA Continuous Professional Development courses including:

- a) Students' Motivation Strategies
- b) Syllabus Design

**B.3.** Memberships in Faculty Committees:

1. Member in the **Faculty Council** (6/2011 – 8/2014)
2. Member in the **Department of Pharmacology & Toxicology Council** (11/2009 - 8/2014)
3. Member in the **PUA Quality Assurance Center** (5/2011- 8/2014)
4. Member in the **Faculty Quality Assurance Unit** (5/2011- 8/2014)
5. Member in the **Faculty Strategic Plan implication committee**



### **Conferences Attended and Abstracts published:**

- *First International Pharmacy conference held by Beirut Arab University, Lebanon, under title of "Recent advances in pharmaceutical research and technology" (6,7 May 2010)*
  - **Oral & Poster presentations of abstracts from Ph.D. thesis as following:**
    - a) R. E. Remonda, **W. H. Maged**, A. I. ElMallah, and I. S. Saad (2010): ***Antitumor Activity of Leflunomide in DMBA-induced Rat mammary Tumors***. Recent advances in pharmaceutical research and technology; 1<sup>st</sup> international conference, Beirut Arab University, Lebanon (May 6-7 2010)
    - b) S. S. Ismail, **W. H. Maged**, A. I. ElMallah, R. E. Risk, and M. Shetaa ***Antitumor Activity Of Celecoxib And Leflunomide On DMBA-Induced Rat Mammary Tumors : Inhibition Of HER-2 Expression (2010):*** Recent advances in pharmaceutical research and technology; Beirut, Lebanon, May 6-7 2010.
    - c) A. I. ElMallah, **W. H. Maged**, Rizk, E. Remonda. ; Ismail, S. Saad. and Ghonein, Hossam. ***Growth Inhibition of DMBA-induced Rat Mammary Tumors by Rosiglitazone and Curcumin Alone or in Combination (2010):*** Recent advances in pharmaceutical research and technology; 1<sup>st</sup> international conference, Beirut Arab University, Lebanon (May 6-7 2010)
- *3rd TERMS World Congress 2012 "Tissue Engineering and Regenerative Medicine Symposium". Vienna, Austria, September 5-8, 2012.*
  - **Poster Presentation under title "Ionically-crosslinked milk protein nanoparticles as glutamide carriers for effective anticancer activity in prostate cancer-bearing rats".**  
Ahmed O. Elzoghby, **Maged W. Helmy**, Wael M. Samy, Nazik A. Elgindy.
- *Experimental Biology 2013 Pharmacology meeting in Boston, MA, USA. April 20-24, 2013. (Poster Presentation)*
  - **3 Poster Presentations as following**
    - a) **Maged W Helmy**, Hanan M El-Gowelli, Rabab M Abdel-Halim and Mahmoud M El-Mas. ***Aggravated Nephrotoxicity Evoked By Concurrent Exposure To Cyclosporine And Indomethacin In Rats: Role Of The Endothelin ETA Receptor/TGF-beta/COX-2 Pathway***. The FASEB Journal. 2013;27:654.10.
    - b) Hanan M El-Gowelli, **Maged W Helmy**, Rabab M Abdel-Halim and Mahmoud M El-Mas. ***Celecoxib Offsets The Negative Renal Influences of Cyclosporine Via COX-2/Endothelin ETB Receptor crosstalk***. The FASEB Journal. 2013;27:654.9
    - c) Mahmoud M El-Mas, Rabab M Abdel-Halim, **Maged W Helmy** and Hanan M El-Gowelli. ***Endothelin ETA/ETB receptors modulate the hemodynamic interaction of cyclosporine with selective and nonselective nonsteroidal anti-inflammatory drugs in rats***. The FASEB Journal. 2013;27:654.8



- *6<sup>th</sup> international Conference held by Medical Research Institute, Alexandria University, 23<sup>rd</sup>-26<sup>th</sup> September 2014, under title of "Multidisciplinary Approach in Cancer Management"*
  - Poster Presentation under title "Potential Growth inhibitory effects of Vitamin D on N-Methyl-N-nitrosourea/Testosterone-induced rat prostate cancer". Maged W. Helmy, Mona A. Salama, Mona K. Maghraby, Noha I. Saad.
- *Experimental Biology 2015 Pharmacology meeting in Boston, MA, USA. April 2015.(Poster Presentation)*
  - M El-Mas, M.W. Helmy, M.M. Helmy. *Additive Renoprotective Effects Of Pioglitazone And Fenofibrate Against Cisplatin-Induced Renal Failure: PPARs/TNF- $\alpha$  Modulation. The FASEB Journal 29 (1 Supplement), 938.5*
- *First PUA International Conference, under title of "Advances in Pharmaceutical Sciences", Faculty of Pharmacy and Drug Manufacturing, Pharos University in Alexandria, Egypt. 27-29, October 2015. (Poster Presentation)*
  - 2 Poster Presentations as following
    - a) Shaimaa Khamis, Maged W. Helmy, Salah Shewita, Ahmed O. Elzoghby. **Novel Tumor-Targeted Protamine Nanocapsules for Combined Delivery of Letrozole and Celecoxib to Breast Cancer Bearing Mice.**
    - b) Maged W Helmy, Gamal M Omran, Sherin M Zakaria. **Antitumor activity of Sulfasalazine in DMBA-induced rat mammary tumors: role of NF- $\kappa$ B, IGF-1 and HER-2 axis inhibition.**
- *4<sup>th</sup> World Congress on Breast Pathology and Cancer Diagnosis (Breast Pathology-2017)", held during August 23-24, 2017 at Toronto, Canada.*
  - Poster Presentation under title "Reversal of TAM Resistance by Calcitriol and Tretinoin Combined Therapy Is Mediated Mainly by Induction of Survivin". Helmy MW, Sakr S, Matta CA, Ahmad MA, El-Abd E.
- *4<sup>th</sup> Future University International Conference of Pharmaceutical Sciences, held on January 31-February 2, 2017, in Cairo, Egypt.*
  - Poster Presentation under title "Evaluation of the potential antitumor effects of Sulfasalazine alone or in combination with Sorafenib on hepatocellular Carcinome cell line" Marium Shamaa, Maged W. Helmy, Hosny Fouad, Medhat Haroun, Nermine Moussa.
- *Experimental Biology 2017 Pharmacology meeting in CHICAGO, USA. April 22-26, 2017.(Poster Presentation)*



- **Maged W. Helmy, Mai M. Helmy and Mahmoud M. El-Mas. Enhanced Lipoygenase/LTD4 Activity Accounts For The Exaggerated Hypertensive And Nephrotoxic Effects Of Cyclosporine Plus Indomethacin In Rats. The FASEB Journal 31 (1 Supplement) Abstract Number: lb541**
- **Experimental Biology 2018 Pharmacology meeting in San Diego, California, USA. April 21-25, 2018. (Poster Presentation)**
  - Mai M. Helmy, **Maged W. Helmy**, and Mahmoud M. El-Mas. Upregulation of cystathionine- $\gamma$ -lyase/hydrogen sulfide pathway underlies the celecoxib counteraction of the cyclosporine-induced hypertension and renal insult in rats. The FASEB Journal 32 (1 Supplement) Abstract Number: 562.9
- **BioVision 2018 Alexandria, Egypt. April 2018. (Poster Presentation)**
  - Abdel Halim M. Elkishky, Nermine Moussa, **Maged W. Helmy**, Medhat Haroun. "In-Vitro Evaluation of the Potential Antitumor Effect of GANT61 and BI-847325 in the Treatment of Lung Cancer"
  - Mohammed Youssef, Nermin Moussa, **Maged W. Helmy**, Medhat Haroun "Evaluation of The Potential Antitumor Effects of Gant61 and/or Dactolisib On Prostate Cancer Cells"
- **1<sup>st</sup> International Pharmaceutical Sciences Conference on 11, 12 August 2018, in Menoufia University, Egypt. (Attendance)**
- **1<sup>st</sup> International Conference on Pharmaceutical & Healthcare Sciences on 6, 7 November 2019, in Faculty of Pharmacy, Alexandria University, Egypt. (2 Poster Presentation)**
  - **Maged W. Helmy**, Asser I. Ghoneim, Mohamed A. Katary, Rana K. Elmahdy. The synergistic anti-proliferative effect of the combination of diosmin and BEZ-235 (dactolisib) on the HCT-116 colorectal cancer cell line occurs through inhibition of the PI3K/Akt/mTOR/NF- $\kappa$ B axis.
  - Doaa M. El-Tedawy, Mohammad M Abd-Alhaseeb, **Maged W. Helmy**, Asser I. Ghoneim. Anti-arthritis activity of systemic bee venom through multiple mechanisms.

### **Workshops Attended**

1. Workshops of "Basic Concepts & Requirements of Quality Assurance and Accreditation of Higher Education" held in 5, 6 June 2008 by National Authority for Quality Assurance and Accreditation of Higher Education (NAQAAE)
2. Workshop of "Basic Techniques in Cell Culture" held in November 2009 by Medical Technology Center for Research, Medical Research Institute, Alexandria University, Egypt



3. Workshops of "**Institutional Self Assessment of Higher Education Institutes**" held in 13-17 December 2009 by National Authority for Quality Assurance and Accreditation of Higher Education (NAQAAE)
4. Workshops of "**External Auditing of Higher Education Institutes**" held in 27-31 December 2009 by National Authority for Quality Assurance and Accreditation of Higher Education (NAQAAE)
5. Continuing Professional Development (CPD) Program in teaching and learning delivered by the Institute of International Education to PUA staff members, 29 & 31 March 2012, at Pharos University in Alexandria.
6. "Basics of Bioinformatics" workshop held by Pharos University in Alexandria, 22 & 23 April, 2012.
7. Workshop of "**Culture and Leadership**" held as a Continuous Professional Development (CPD) Program, delivered by the Institute of International Education to PUA staff members. **5 January 2014, at Pharos University in Alexandria.**
8. Training Course on "**Effective Presentation Skills**", organized by Faculty and leadership Development Center, Alexandria University, 8-9 March 2014.
9. Training Course on "**The Credit Hour System**", organized by Faculty and leadership Development Center, Alexandria University, 15-16 March 2014.
10. Workshop of "**Gene expression analysis on large scale using Microarray and Real-Time PCR techniques**" held in Molecular Biology Lab, Cairo University Research Park, 8<sup>th</sup>-11<sup>th</sup> September, 2014.
11. Workshop of "**Pharmaceutical Vigilance**" held in Damanhour, Elbahira, Egypt, February 23<sup>rd</sup> 2015 under supervision of Egyptian Pharmaceutical Vigilance Center.
12. Workshop of "**Application of Pharmacy NARS: from Content to Competency-based Curricula**" held by National Authority for Quality Assurance and Accreditation of Higher Education (NAQAA) and Agence Universitaire de la Francophonie (AUF) on 18<sup>th</sup> & 19<sup>th</sup> December 2017, Cairo, Egypt.
13. Workshop of "**The Future of Biotechnology in Egypt**" held in Damanhour, Elbahira, Egypt, 5<sup>th</sup> February 2018 under supervision of Damanhour University.
14. Workshop of "**Developing Institutional Internationalization**" held by National Erasmus+ office on 14<sup>th</sup> & 15<sup>th</sup> May 2018, Alexandria, Egypt.
15. Workshop of "**Blended E-Learning Skills**" held in Damanhour, Elbahira, Egypt, August 6-7 2018 under supervision of E-Learning & Management Center, Damanhour University.
16. Workshop of "**Isolation of Mesenchymal Stem Cells from Rats**" held in CERRMA unit, Faculty of Medicine, Alexandria University, Egypt, July 16-17 2019
17. Workshop of "**Research Methods**" held in FLDC unit, Damanhour University, Egypt, August 19-20, 2019.
18. Workshop of "**University Management**" held in FLDC unit, Damanhour University, Egypt, August 21-22, 2019.



19. Workshop of "Innovative Problem-solving and Decision-making" held in FLDC unit, Alexandria University, Egypt, April 25-26, 2020.
20. Workshop of "E-Exam" held in FLDC unit, Alexandria University, Egypt, April 29-30, 2020.

### **Research Projects membership**

1. **Project ID: 5731, Code: TC/3/April/2013/DNPI5731 (Targeted Call; Towards Development of National Pharmaceuticals Industries), "Inhalable Anticancer Drug-loaded Nanocomposites for Enhanced Lung Cancer Targeting";** Science & Technology Development Fund (STDF), Ministry of Scientific Research, Egypt. Role in the project: **CO-PI.**
2. **Project ID: 15053 (Innovation Grant), "Synthesis and evaluation of drug-polymer conjugate nanomicelles as emerging platform for targeted brain tumor therapy";** Science & Technology Development Fund (STDF), Ministry of Scientific Research, Egypt. Role in the project: **Partner.**
3. **Project ID: 25717 (Young Researcher – Call 7), "Design and Synthesis of novel selective Estrogen Receptor modulators";** Science & Technology Development Fund (STDF), Ministry of Scientific Research, Egypt. Role in the project: **CO-PI.**

### **Patent Registration:**

1. **Patent Application No.: 554/2017- Ministry of Scientific Researches, Academy of Scientific Research and Technology (Alexandria Office)**  
**Title:** Multi-compartmental nano-structural vehicle for co-delivery of resveratrol, monascin and ankaflavin for breast cancer treatment  
**Inventors:** Shaymaa W El-Far, **Helmy Wasfy Helmy**, Sherine N Khattab, Adnan A Bekhit, Ahmed A Hussein, Ahmed O. Elzoghby.
2. **Patent Application No.: 1579/2017- Ministry of Scientific Researches, Academy of Scientific Research and Technology (Alexandria Office)**  
**Title:** Mannosylated albumin-quantum dot nano-theranostics for breast cancer  
**Inventors:** Dina G. Zayed, Shaker M. Ebrahim, **Helmy Wasfy Helmy**, Sherine N. Khattab, Kadria A. Elkhodairy and Ahmed O. Elzoghby.
3. **Patent Application No.: 1581/2017- Ministry of Scientific Researches, Academy of Scientific Research and Technology (Alexandria Office)**  
**Title:** Amphiphilic zein-lactoferrin nanomicelles for targeted drug delivery to breast cancer  
**Inventors:** Sally A. Sabraa, Ahmed O. Elzoghby, Salah A. Sheweita, Medhat Haroun, **Maged W. Helmy.**
4. **Patent Application No.: 420/2018- Ministry of Scientific Researches, Academy of Scientific Research and Technology (Alexandria Office)**



**Title:** Amphiphilic maltodextrin-based polymeric micelles for tumor-targeted drug delivery

**Inventors:** Anwar DM, Khattab SN, Helmy Wasfy Helmy, Kamal MK, Bekhit AA, Elkhodairy KA, Elzoghby AO.

5. **Patent Application No.: 957/2018 - Ministry of Scientific Researches, Academy of Scientific Research and Technology (Main Office, Cairo, Egypt). Presented by STDF via Project ID: 5731, Code: TC/3/April/2013/DNPI5731**

**Title:** Inhalable lactoferrin-chondroitin dual-targeted cubosomal nanocomposites for enhanced lung cancer targeting

**Inventors:** STDF co-Inventors: Ahmed Elzoghby, Hadeer Mamdouh, Helmy Wasfy Helmy, Magda Samaha

6. **Patent Application No.: 1119/2018- Ministry of Scientific Researches, Academy of Scientific Research and Technology (Main Office, Cairo, Egypt). Presented by STDF via Project ID: 5731, Code: TC/3/April/2013/DNPI5731**

**Title:** Inhalable hyaluronate/lactoferrin-decorated lipid nanocomposites for localized drug delivery to lung cancer

**Inventors:** STDF co-Inventors: Ahmed Elzoghby, Dalia Kabary, Helmy Wasfy Helmy, Kadria Elkhodairy

7. **Patent Application No.: 1501/2018- Ministry of Scientific Researches, Academy of Scientific Research and Technology (Main Office, Cairo, Egypt). Presented by STDF via Project ID: 5731, Code: TC/3/April/2013/DNPI5731**

**Title:** Inhalable dual-targeted protein-lipid nanocomposites for enhanced lung cancer targeting

**Inventors:** STDF co-Inventors: Ahmed Elzoghby, Nayera Kamel, Helmy Wasfy Helmy, Magda Samaha

8. **Patent Application No.: 1479/2019- Ministry of Scientific Researches, Academy of Scientific Research and Technology (Main Office, Cairo, Egypt). Presented by STDF via Project ID: 5731, Code: TC/3/April/2013/DNPI5731**

**Title:** Amphiphilic zein-chondroitin magnetic nanomicelles as cancer theranostics

**Inventors:** STDF co-Inventors: Ahmed Elzoghby, Kholod Elhasani, Helmy Wasfy Helmy, Adnan Bekhit, Sherine Khattab.

9. **Patent Application No.: 1610/2019- Ministry of Scientific Researches, Academy of Scientific Research and Technology (Main Office, Cairo, Egypt). Presented by STDF via Project ID: 5731, Code: TC/3/April/2013/DNPI5731**

**Title:** Lactoferrin-mesoporous silica nanohybrids for tumor-targeted chemo-herbal drug delivery

**Inventors:** STDF co-Inventors: Ahmed Elzoghby, Omnia Ali, Helmy Wasfy Helmy, Adnan Bekhit, Sherine Khattab.

10. **Patent Application No.: 536/2020- Ministry of Scientific Researches, Academy of Scientific Research and Technology (Alexandria Office)**

**Title:** Nanoparticles Loaded with food-based bioactive compounds in treatment of Infected lung cancer

**Inventors:** Marian Gerges Wahieb, Sana H. Omar, Rowida Kalil Salah Eldin, Heba Khairy Hassen, Ahmed O. Elzoghby Helmy Wasfy Helmy.



## Membership of Professional Societies:

1. Egyptian Pharmacist Syndicate (EPS) – ID:37924
2. Member of Egyptian Society of Natural Toxins (ESNT), membership No.: 947

## Dissertation Supervision (completed& in progress)

### A. Completed thesis:

1. Thesis Master Degree, Faculty of Pharmacy, Alexandria University. "**Role of nitrenergic and/or endothelin modulation in the cisplatin-induced acute renal failure in male rats**" as a co-supervision with Prof. Dr. Mahmoud Mohey El-Din and Dr. Mai MoustafaHelmy, 2013.
2. Thesis of Master Degree, Medical Researches Institute, Alexandria University. "**Evaluation of the anti-carcinogenic action of  $\beta$ -adrenergic receptor blockade or dopaminergic receptors stimulation in experimentally induced rat mammary tumors**" as a co-supervision with Prof. Dr. Remonda E. Rizk and Dr. Wessam F. El Hadidy, 2013.
3. Thesis of Master Degree, Medical Researches Institute, Alexandria University. "**Evaluation of the anti-carcinogenic action with possible novel targets for treatments of experimentally induced prostate cancer in male rats**" as a co-supervision with Dr. Mona Abdel RazekSalama and Dr. Dr. Hala Khalil El-Maghraby, 2013.
4. Thesis of Master Degree, Faculty of Pharmacy, Alexandria University. "**The renal and hemodynamic effects of cyclosporine and nonsteroidalantiinflammatory drugs in rats**" as a co-supervision with Prof. Dr. Mahmoud El Mass and Dr. HananElgwalely, 2013.
5. Thesis of PhD degree, Medical Researches Institute, Alexandria University. "**A comparative study of the effect of different Tyrosine Kinase Inhibitors on some signaling pathways in breast cancer cell line**" as a co-supervision with Prof. Dr. Remonda E. Rizk and Dr. RoidaRefaat , 2016.
6. Thesis of PhD degree, Institute of Graduate Studies and Research, Department of Biotechnology. "**BiopolymericNanovehicular Drug Delivery Systems for Targeted Cancer Therapy**" as a co-supervision with Prof. Dr. Salah A. Sheweita, Prof. Dr. Maha A. El Demellawy and Dr. Ahmed O. Elzoghby, 2016.
7. Thesis of PhD degree, Faculty of Pharmacy, Cairo University. "**Evaluation of the potential mechanisms involved in the renal therapeutic effect of Vitamin D and/or Pioglitazone on ischemia reperfusion injury induced in male rats**" as a co-supervision with Prof. Dr. Hanan Salah El Din El-Abhar and Dr. Muhammad Yusuf Al-Shorbagy , 2018.
8. Thesis of Master degree, Medical Researches Institute, Alexandria University. "**Comparative effectiveness of Berberine/tamoxifen combination versus Diosmin/tamoxifen in breast cancer cell line**" as a co-supervision with Prof. Dr. Remonda E. Rizk and Ass. Prof. Dr. RoidaRefaat , 2016.
9. Thesis of PhD degree, Faculty of Pharmacy, Cairo University. "**Evaluation of the potential anti-carcinogenic effects of re-expressing and/or stimulating estrogen receptor-beta in the**



**prostate cancer cell line PC3" as a co-supervision with Prof. Dr. Tarek M. Mettawae, Prof. Dr. Iman H. Diab and Dr. Hebatallah Darwish, 2019.**

10. *Thesis of PhD degree, Faculty of Pharmacy, Cairo University. " Evaluation of the potential renoprotective effect of Vitamin D and/or retinoic acid on cisplatin-induced nephrotoxicity in male rats and their possible interaction with endothelin-1 pathway" as a co-supervision with Prof. Dr. Hanan Salah El Din El-Abhar. 2019*
11. *Thesis of Master degree, Medical Researches Institute, Alexandria University. "Evaluation of the Potential Anti-carcinogenic Effects of Re-expressing Estrogen Receptor Beta on Breast Cancer Cell Line in the Presence or Absence of Either Tamoxifen or Raloxifen" as a co-supervision with Prof. Dr. Remonda E. Rizk and Dr. Roida Refaat , 2016.*
12. *Thesis of PhD degree, Institute of Graduate Studies and Research, Alexandria University. "Evaluation of the potential antitumor effects of Sulfasalazine and Sorafenib either alone or in combination on Hepatocellular Carcinoma cell line" as a co-supervision with Prof. Dr. Medhat Abou Goma Mohamed Haroun, Prof. Dr. Housny Fouad and Dr. Nermin Aly Moussa, 2017.*
13. *Thesis of PhD degree, Institute of Graduate Studies and Research, Alexandria University. "Evaluation of the potential antitumor effects of Dasatinib and Celecoxib either alone or in combination on Colon Cancer cell line" as a co-supervision with Prof. Dr. Medhat Abou Goma Mohamed Haroun, Prof. Dr. Housny Fouad and Dr. Nermin Aly Moussa , 2017.*
14. *Thesis of PhD degree, Medical Researches Institute, Alexandria University. "Evaluation of insulin like growth factor pathway as a potential target for restoring tamoxifen sensitivity in breast cancer cell line" as a co-supervision with Prof. Dr. Remonda E. Rizk and Ass. Prof. Roida Refaat , 2018.*
15. *Thesis of Master degree, Medical Researches Institute, Alexandria University. "Evaluation of the Potential Antitumor Effect of Honokiol Alone or in Combination with Sorafenib on Hepatocellular Carcinoma Cell Line " as a co-supervision with Prof. Dr. Magda Nasr and Ass. Prof. Roida Refaat, 2018.*
16. *Thesis of Master degree, Medical Researches Institute, Alexandria University. "Evaluation of the potential antitumor effect of Dasatininb alone or in combination with BEZ 235 on Hepatocellular Carcinoma cell line " as a co-supervision with Prof. Dr. Magda Nasr and Ass. Prof. Roida Refaat, 2018.*
17. *Thesis Master Degree, Faculty of Pharmacy, Alexandria University. "Drug Delivery Nano-System as a non invasive targeted therapy for Lung Cancer" as a co-supervision with Prof. Dr. Magda W. Samaha and Dr. Ahmed O. ElZoghby, 2018.*
18. *Thesis Master Degree, Faculty of Pharmacy, Alexandria University. "Lipoprotein Nanovehicular System as a Targeted Therapy of Cancer" as a co-supervision with Prof. Dr. Magda W. Samaha and Dr. Ahmed O. ElZoghby, 2018.*
19. *Thesis Master Degree, Faculty of Pharmacy, Alexandria University. "Albumin Nanoparticles as Targeted Drug Delivery System of Cancer " as a co-supervision with Prof. Dr. Magda W. Samaha and Dr. Ahmed O. ElZoghby, 2018.*
20. *Thesis of Master degree, Institute of Graduate Studies and Research, Alexandria University. "Evaluation of the Potential Antitumor Effects of GANT61and / or Dactolisib On Prostate*

- Cancer Cell Line" as a co-supervision with Prof. Dr. Medhat Abou Goma Mohamed Haroun and Dr. Nermin Aly Moussa , 2018.**
21. Thesis of Master degree, Institute of Graduate Studies and Research, Alexandria University. **"Evaluation of the potential antitumor effects of GANT61 and BI-847325 either alone or in combination on lung adenocarcinoma cell line" as a co-supervision with Prof. Dr. Medhat Abou Goma Mohamed Haroun and Dr. Nermin Aly Moussa , 2018.**
  22. Thesis of Master degree, Institute of Graduate Studies and Research, Alexandria University. **"Evaluation of the potential antitumor effects of IMR-1 and BRI-724 either alone or in combination on lung adenocarcinoma cell line" as a co-supervision with Prof. Dr. Medhat Abou Goma Mohamed Haroun and Dr. Nermin Aly Moussa , 2019.**
  23. Thesis of Master degree, Institute of Graduate Studies and Research, Alexandria University. **"Evaluation of the potential antitumor effects of Pioglitazone either alone or in combination with Dasatinib on Hepatocellular Carcinoma cell line" as a co-supervision with Prof. Dr. Salah A. Sheweita , 2019**
  24. Thesis of Master degree, Institute of Graduate Studies and Research, Alexandria University. **"Evaluation of the Potential Antitumor Effects of resulting from co- targeting of SRC and COX-2 signaling pathways in triple negative breast cancer cell line" as a co-supervision with Prof. Dr. Medhat Abou Goma Mohamed Haroun and Dr. Nermin Aly Moussa , 2019.**
  25. Thesis of Master degree, Faculty of Pharmacy, Damanhour University. **"Evaluation of antitumor effect of a combination of a cyclooxygenase inhibitor and a phytochemical on liver cancer" as a co-supervision with Prof. Dr. Asser I. Ghoniem and Ass.Prof. Dr. Mohamed Alaa Hattary, 2019.**
  26. Thesis of PhD degree, Faculty of Pharmacy, Cairo University. **"Evaluation of the potential anti-carcinogenic pathways of either rosuvastatin and/or dasatinib in different experimental models of Hepatocellular carcinoma" as a co-supervision with Prof. Dr. Hanan Salah El Din El-Abhar, 2019.**
  27. Thesis of Master degree, Faculty of Pharmacy, Cairo University. **"Evaluation of the Potential Antitumor Effects of GLI inhibitor "GANT61" alone or in Combination with Celecoxib on Colorectal Carcinoma Cell Line" as a co-supervision with Prof. Dr. Hanan Salah El Din El-Abhar, 2020.**
  28. Thesis of Master degree, Faculty of Pharmacy, Damanhour University. **"Pharmacological Evaluation of Selected Anti-Alzheimer Drugs" as a co-supervision with Prof. Dr. Asser I. Ghoniem and Ass.Prof. Dr. Mohamed Alaa Hattary, 2020.**
  29. Thesis of Master degree, Faculty of Pharmacy, Damanhour University. **"Evaluation of the potential anti-tumor effects of drugs targeting multiple signaling pathways in colorectal cancer cell line" as a co-supervision with Prof. Dr. Asser I. Ghoniem and Ass.Prof. Dr. Mohamed Alaa Hattary, 2020.**

### **B. In progress thesis:**

1. Thesis of PhD degree, Medical Researches Institute, Alexandria University. **" Evaluation of the Potential Antitumor Effect of Thioridazine Hydrochloride Alone or in Combination with Sorafenib on Hepatocellular Carcinoma Cell Line " as a co-supervision with Prof. Dr. Magda Nasr and Ass. Prof. Dr. Roida Refaat, 2017.**
2. Thesis of Master degree, Faculty of Pharmacy, Damanhour University. **" Evaluation of the potential anti-tumor effects resulting from co-targeting of multiple signaling pathways on**



- lung adenocarcinoma cell line" as a co-supervision with Prof. Dr. Asser I. Ghoniem and Ass.Prof. Dr. Mohamed Alaa Hattary, 2016
3. Thesis of Master degree, Faculty of Pharmacy, Damanhour University. **"Evaluation of the potential renoprotective effects of Etanercept on Cisplatin-induced nephrotoxicity in male rats"** as a co-supervision with Prof. Dr. Asser I. Ghoniem and Ass.Prof. Dr. Mohamed Alaa Hattary, 2018
  4. Thesis of Master degree, Faculty of Pharmacy, Damanhour University. **"Evaluation of the potential renoprotective effects of Diosmine on Cisplatin-induced nephrotoxicity in male rats"** as a co-supervision with Prof. Dr. Asser I. Ghoniem and Dr. Mohamed Abdel Hasseb, 2018.
  5. Thesis of PhD degree, Medical Researches Institute, Alexandria University. **"Evaluation of the potential anti-tumoreffects of vitamin A and/or PD-L1 cellular checkpoint inhibitor on hepatocellular carcinoma cell lines"** as a co-supervision with Prof. Dr. Magda Nasr and Ass. Prof. Dr. Dr. Raghda Abo Ayana, 2018.
  6. Thesis of Master degree, Institute of Graduate Studies and Research, Alexandria University. **"Enhancing Antitumor efficiency of Regorafenib by combination with berberine on Hepatocellular Carcinoma Cell Line"** as a co-supervision with Prof. Dr. Salah A. Showeita, 2018.
  7. Thesis Master Degree, Faculty of Pharmacy, Alexandria University. **"Evaluation of the combined antitumor effect of pioglitazone and the tyrosine kinase inhibitor dactolisib in experimental model of hepatocellular carcinoma"** as a co-supervision with Prof. Dr. Housny Fouad, Prof. Dr. Ahmed El Mallah, Prof. Dr. Elham A. Afifi, 2016.
  8. Thesis of Master degree, Institute of Graduate Studies and Research, Alexandria University. **"Enhancing the co-delivery of Cox-2 and tyrosine Kinase as a breast cancer therapy using a nanosystem approach"** as a co-supervision with Prof. Dr. Medhat Abou Gomaa Mohamed Haroun, Dr. Nermin Aly Moussa and Dr. Sally A. Sabra, 2019
  9. Thesis of Master degree, Institute of Graduate Studies and Research, Alexandria University. **"Using Protein derived Nanovehicular system loaded with Dasatinib and Celecoxib for oral squamous cancer cell line "** as a co-supervision with Prof. Dr. Medhat Abou Gomaa Mohamed Haroun, Dr. Nermin Aly Moussa and Dr. Sally A. Sabra, 2019
  10. Thesis of PhD degree, Institute of Graduate Studies and Research, Alexandria University. **"Evaluation of the potential anti-tumoreffects of AbemaceclibeandCelecoxibeither alone or in combination on Colon Cancer cell line"** as a co-supervision with Prof. Dr. Medhat Abou Gomaa Mohamed Haroun and Dr. Nermin Aly Moussa, 2020.
  11. Thesis of Master degree, Faculty of Pharmacy, Damanhour University. **"Evaluation of the Anti-inflammatory Effects of Bee- Venom on Rheumatoid Arthritis Model"** as a co-supervision with Prof. Dr. Asser I. Ghoniem and Ass.Prof. Dr. Mohamed Alaa Hattary, 2017.
  12. Thesis of Master degree, Faculty of Pharmacy, Damanhour University. **"Clinical Protective Effects of Selected Drugs against Chemotherapy Induced Side Effects"** as a co-supervision with Prof. Dr. Asser I. Ghoniem and Ass.Prof. Dr. Mohamed Alaa Hattary, 2017
  13. Thesis of Master degree, Faculty of Pharmacy, Damanhour University. **"Evaluation of the potential anti-tumor effects resulting from targeting of PD-L1 cellular checkpoint pathway on lung adenocarcinoma cell line"** as a co-supervision with Prof. Dr. Asser I. Ghoniem and Ass.Prof. Dr. Mohamed Alaa Hattary, 201
  14. Thesis of Master degree, Faculty of Pharmacy, Damanhour University. **"Role of Hedgehog signaling pathway on programmed death ligand-1(PD-L1) expression in colorectal**



- cancer(CRC) cell line" as a co-supervision with Ass.Prof. Dr. Mohamed Alaa Hattary and Dr. Mohamed Abdel Hasseb, 2017
15. Thesis of Master degree, Faculty of Pharmacy, Damanhour University. **"Role of Selected Drugs against Doxorubicin/Cyclophosphamide induced side effects"** as a co-supervision with Prof. Dr. Asser I. Ghoniem and Ass.Prof. Dr. Mohamed Alaa Hattary, 2017
  16. Thesis of PhD degree, Faculty of Pharmacy, Damanhour University. **"Modulatory Effects of Selected Amino Acids on Signaling Pathways on Hepatocellular carcinoma cell line"** as a co-supervision with Prof. Dr. Asser I. Ghoniem and Ass.Prof. Dr. Mohamed Alaa Hattary, 2018
  17. Thesis of Master degree, Faculty of Pharmacy, Damanhour University. **"Evaluation of the potential anti-tumoreffects of Regorafenib and Catalpoleither alone or in combination on Hepatocellular carcinoma cell line"** as a co-supervision with Ass.Prof. Dr. Mohamed Alaa Hattary and Mohamed Abdel Hasseb, 2019.

### Publications:

1. [Helmy M.W.](#), Sharabi F.M., Rizk R.E., and Ismail S.S. (2005): **Comparative effects of tamoxifen versus anastrozole in an experimental mammary carcinogenesis model.** JMRI., 26: 1-6.
2. Ahmed O. Elzoghby, [Maged W. Helmy](#), Wael M. Samy, Nazik A. Elgindy. **Novel ionically crosslinked casein nanoparticles for flutamide delivery: formulation, characterization, and in vivo pharmacokinetics.** International Journal of Nanomedicine. 2013;8 1721–1732
3. Ahmed O. Elzoghby, [Maged W. Helmy](#), Wael M. Samy, Nazik A. Elgindy. **Spray-dried casein-based micelles as a vehicle for solubilization and controlled delivery of flutamide: Formulation, characterization, and in vivo pharmacokinetics** Eur. J. Pharm. Biopharm. 2013 Aug;84(3):487-96
4. Ahmed O. Elzoghby, [Maged W. Helmy](#), Wael M. Samy, Nazik A. Elgindy. **Micellar delivery of flutamide via milk protein nanovehicles enhances its anti-tumor efficacy in androgen-dependent prostate cancer rat model.** Pharm. Res. 2013 Oct;30(10):2654-63
5. Ahmed O. Elzoghby, Noha I. Saad, [Maged W. Helmy](#), Wael M. Samy, Nazik A. Elgindy. **Ionically-crosslinked milk protein nanoparticles as flutamide carriers for effective anticancer activity in prostate cancer-bearing rats.** Eur J Pharm Biopharm. 2013 Aug;85(3):444-51
6. Hanan M. El-Gowelli, [Maged W. Helmy](#), Rabab M. Ali, Mahmoud M. El-Mas. **Celecoxib offsets the negative renal influences of cyclosporine via modulation of the TGF- $\beta$ 1/IL-2/COX-2/endothelin ETB receptor cascade.** Toxicology and Applied Pharmacology. 2014. Toxicology and Applied Pharmacology 275 (2014) 88–95
7. Mai M. Helmy, [Maged W. Helmy](#), Dina M. Abd Allah, Ahmad M. Abo Zaid, Mahmoud M. Mohy El-Din Mohy El-Din. **Selective ETA receptor blockade protects against cisplatin-induced acute renal failure in male rats.** European Journal of Pharmacology 730 (2014) 133–139
8. [Maged W. Helmy](#), Mai M. Helmy, Dina M. Abd Allah, Ahmad M. Abo Zaid, Mahmoud M. Mohy El-Din Mohy El-Din. **Role of nitrenergic and endothelin pathways modulations in cisplatin-induced nephrotoxicity in male rats.** JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY 2014, 65, 3, 393-399

9. Mahmoud M El-Mas, [Maged W Helmy](#), Rabab M Abdel-Halim, and Hanan M El-Gowelli. *Celecoxib, but not indomethacin, ameliorates the hypertensive and perivascular fibrotic actions of cyclosporine in rats: Role of endothelin signaling*. *Toxicology and Applied Pharmacology* 284 (2015) 1–7.
10. [Maged W. Helmy](#), Hanan M. El-Gowelli, Rabab M. Ali, Mahmoud M. El-Mas. *Endothelin ETA receptor/lipid peroxides/COX-2/TGF- $\beta$ 1 signaling underlies aggravated nephrotoxicity caused by cyclosporine plus indomethacin in rats*. *British Journal Of Pharmacology* 05/2015; DOI: 10.1111/bph.13199
11. MM Helmy, [MW Helmy](#), MM El-Mas. *Additive Renoprotection by Pioglitazone and Fenofibrate against Inflammatory, Oxidative and Apoptotic Manifestations of Cisplatin Nephrotoxicity: Modulation by PPARs*. *PloS one*, 2015; 10 (11), e014230.
12. AS Hanafy, RM Farid, [MW Helmy](#), SS ElGamal. *Pharmacological, toxicological and neuronal localization assessment of galantamine/chitosan complex nanoparticles in rats: future potential contribution in Alzheimer's disease management*. *Drug delivery*, 2016
13. Elzoghby AO, Mostafa SK, [Helmy MW](#), El-Demellawy M, Shewita S, *Superiority of aromatase inhibitor and cyclooxygenase-2 inhibitor combined delivery: Hyaluronate-targeted versus PEGylated protamine nanocapsules for breast cancer therapy*, *Int J Pharm* 529 (2017) 178-192.
14. Elzoghby AO, Mostafa SK, [Helmy MW](#), El-Demellawy M, Shewita S. *Multi-Reservoir Phospholipid Shell Encapsulating Protamine Nanocapsules for Co-Delivery of Letrozole and Celecoxib In Breast Cancer Therapy*. *Pharm Res* 34 (2017) 1956–1969.
15. Ahmed O Elzoghby, Sarah A El-Lakany, [Maged W Helmy](#), Marwa M Abu-Serie, Nazik A Elgindy. *Shell-crosslinked zein nanocapsules for oral codelivery of exemestane and resveratrol in breast cancer therapy*. *Nanomedicine* 12 (24) (2017), 2785-2805
16. Shaymaa W El-Far, [Maged W Helmy](#), Sherine N Khattab, Adnan A Bekhit, Ahmed A Hussein, Ahmed O Elzoghby. *Phytosomal bilayer-enveloped casein micelles for codelivery of monascus yellow pigments and resveratrol to breast cancer*. *Nanomedicine* 13 (5) (2018), 481-499
17. [Maged W Helmy](#), Mai M Helmy, Mahmoud M El-Mas. *Enhanced lipooxygenase/LTD4 activity accounts for the exaggerated hypertensive and nephrotoxic effects of cyclosporine plus indomethacin in rats*. *Biomedicine & Pharmacotherapy* (2018) 102, 309-316
18. Dalia M Kabary, [Maged W Helmy](#), Kadria A Elkhodairy, Jia-You Fang, Ahmed O Elzoghby. *Hyaluronate/lactoferrin layer-by-layer-coated lipid nanocarriers for targeted co-delivery of rapamycin and berberine to lung carcinoma*. *Colloids and Surfaces B: Biointerfaces* (2018) 169, 183-194
19. Sally A Sabra, Ahmed O Elzoghby, Salah A Sheweita, Medhat Haroun, [Maged W Helmy](#), Maha A El-Demellawy, Ying Xia, David Goodale, Alison L Allan, Sohrab Rohani. *Self-assembled amphiphilic zein-lactoferrin micelles for tumor targeted co-delivery of rapamycin and wogonin to breast cancer*. *European Journal of Pharmaceutics and Biopharmaceutics* (2018) 128, 156-169
20. Mayada M Elgohary, [Maged W Helmy](#), Elsayeda-Zeinab A Abdelfattah, Doaa M Ragab, Sana M Mortada, Jia-You Fang, Ahmed O Elzoghby. *Targeting sialic acid residues on lung cancer cells by inhalable boronic acid-decorated albumin nanocomposites for combined chemo/herbal therapy*. *Journal of Controlled Release* (2018) 285, 230-243

21. Rabab M Ali, Muhammad Y Al-Shorbagy, [Maged W Helmy](#), Hanan S El-Abhar. **Role of Wnt4/ $\beta$ -catenin, Ang II/tgfb, Ace2, Nf- $\kappa$ b, and IL-18 in attenuating renal ischemia/reperfusion-induced injury in rats treated with Vit D and pioglitazone.** European journal of pharmacology (2018) 831, 68-76
22. Tarek K Motawi, Hebatallah A Darwish, ImanDiab, [Maged W Helmy](#), Mohamed H Noureldin. **Combinatorial strategy of epigenetic and hormonal therapies: A novel promising approach for treating advanced prostate cancer.** Life sciences (2018) 198, 71-78
23. [Maged W. Helmy](#), Mai M. Helmy, Mahmoud M. El-Mas. **Enhanced lipoxigenase/LTD4 signaling accounts for the exaggerated hypertensive and nephrotoxic effects of cyclosporine plus indomethacin in rats.** Biomedicine & Pharmacotherapy 102 (2018) 309–316.
24. Shaymaa W El-Far, [Maged W Helmy](#), Sherine N Khattab, Adnan A Bekhit1, Ahmed A Hussein & Ahmed O Elzoghby. **Folate conjugated vs PEGylated phytosomal casein nanocarriers for codelivery of fungal and herbal-derived anticancer drugs.** Nanomedicine (Lond.) (2018) 13(12), 1463–1480
25. Rabab M. Alia, Muhammad Y. Al-Shorbagy, [Maged W. Helmy](#), Hanan S. El-Abhar. **Role of Wnt4/ $\beta$ -catenin, Ang II/TGF $\beta$ , ACE2, NF- $\kappa$ B, and IL-18 in attenuating renal ischemia/reperfusion-induced injury in rats treated with Vit D and pioglitazone.** European Journal of Pharmacology 831 (2018) 68–76
26. Sally A. Sabraa, Ahmed O. Elzoghby, Salah A. Sheweita, Medhat Haroun, [Maged W. Helmy](#), Maha A. Eldemellawy, Ying Xiag, David Goodale, Alison L. Allang, Sohrab Rohani. **Self-assembled amphiphilic zein-lactoferrin micelles for tumor targeted codelivery of rapamycin and wogonin to breast cancer.** European Journal of Pharmaceutics and Biopharmaceutics 128 (2018) 156–169
27. Ahmed S AbdElhamid, [Maged W Helmy](#), Shaker M Ebrahim, Mohammed Bahey-El-Din, Dina G Zayed, Esmat A Zein El Dein, Sanaa A El-Gizawy & Ahmed O Elzoghby. **Layer-by-layer gelatin/chondroitin quantum dots-based nanotheranostics: combined rapamycin/celecoxib delivery and cancer imaging.** Nanomedicine (Lond). 2018 Aug 3. doi: 10.2217/nnm-2018-0028.
28. Dalia M. Kabary, [Maged W. Helmy](#), Kadria A. Elkhodairy, Jia-You Fange, Ahmed O. Elzoghby. **Hyaluronate/lactoferrin layer-by-layer-coated lipid nanocarriers for targeted co-delivery of rapamycin and berberine to lung carcinoma.** Colloids and Surfaces B: Biointerfaces 169 (2018) 183–194
29. Mahmoud M AbdElwakil, Moustafa T Mabrouk, [Maged W Helmy](#), Elsayeda-Zeinab A Abdelfattah, Sachin K Khiste, Kadria A Elkhodairy & Ahmed O Elzoghby. **Inhalable lactoferrin-chondroitin nanocomposites for combined delivery of doxorubicin and ellagic acid to lung carcinoma.** Nanomedicine (Lond). 2018 Aug; 13(16):2015-2035.
30. Dalia M. Kabary, [Maged W. Helmy](#), Elsayeda-Zeinab A. Abdelfattah, Jia-You Fang, Kadria A. Elkhodairy, Ahmed O. Elzoghby. **Inhalable multi-compartmental phospholipid enveloped lipid core nanocomposites for localized mTOR inhibitor/herbal combined therapy of lung carcinoma.** European Journal of Pharmaceutics and Biopharmaceutics 130 (2018) 152–164
31. Mayada M. Elgohary, [Maged W. Helmy](#), Elsayeda-Zeinab A. Abdelfattah, Doaa M. Ragabb, Sana M. Mortada, Jia-You Fange, Ahmed O. Elzoghby. **Targeting sialic acid residues on**

- lung cancer cells by inhalable boronic acid decorated albumin nanocomposites for combined chemo/herbal therapy.* Journal of Controlled Release 285 (2018) 230–243
32. Mayada M Elgohary, [Maged W Helmy](#), Sana M Mortada & Ahmed O Elzoghby. **Dual-Targeted Nano-in-Nano Albumin Carriers Enhance The Efficacy of Combined Chemo/Herbal Therapy of Lung Cancer.** Nanomedicine (Lond). 2018 Sep; 13(17):2221-2224. doi: 10.2217/nnm-2018-0097.
33. Ahmed S Abdelhamid, Dina G Zayed, [Maged W Helmy](#), Shaker M Ebrahim, Mohammed Bahey-El-Din, Esmat A Zein-El-Dein, Sanaa A El-Gizawy & Ahmed O Elzoghby. **Lactoferrin-tagged quantum dots-based theranostic nanocapsules for combined COX-2 inhibitor/herbal therapy of breast Cancer.** Nanomedicine (Lond). 2018 Oct 19. doi: 10.2217/nnm-2018-0196
34. Anwar DM, Khattab SN, [Helmy MW](#), Kamal MK, Bekhit AA, Elkhodairy KA, Elzoghby AO. **Lactobionic/Folate Dual-Targeted Amphiphilic Maltodextrin-Based Micelles for Targeted Codelivery of Sulfasalazine and Resveratrol to Hepatocellular Carcinoma.** Bioconjug Chem. 2018 Sep 19;29(9):3026-3041.
35. Sarah A. El-Lakany, Nazik A. Elgindy, [Maged W. Helmy](#), Marwa M Abu-Serie & Ahmed O. Elzoghby. **Lactoferrin-decorated vs. PEGylated zein nanospheres for combined aromatase inhibitor and herbal therapy of breast cancer.** Expert Opin Drug Deliv. 2018 Sep; 15(9):835-850.
36. Mona A. Abdelmoneem, Mazen Mahmoud, Amira Zaky, [Maged W. Helmy](#), Marwa Sallam, Jia-You Fang, Kadria A. Elkhodairy, Ahmed O. Elzoghby. **Dual-targeted casein micelles as green nanomedicine for synergistic phytotherapy of hepatocellular carcinoma.** Journal of Controlled Release 287 (2018) 78–93
37. Fatma M. Abdallah, [Maged W. Helmy](#), Mohamed A. Katary, Asser I. Ghoneim. **Synergistic antiproliferative effects of curcumin and celecoxib in hepatocellular carcinoma HepG2 cells.** Naunyn-Schmiedeberg's Arch Pharmacol. 2018 Dec; 391(12):1399-1410.
38. Sherin Zakariaa, [Maged Wasfy Helmy](#), Ahmed Salahuddin, Gamal Omran. **Chemopreventive and antitumor effects of benzyl isothiocyanate on HCC models: A possible role of HGF /pAkt/ STAT3 axis and VEGF.** Biomedicine & Pharmacotherapy 108 (2018) 65–75
39. Ibrahim El Sayed, [Maged W. Helmy](#), Hanan S. El-Abhar. **Inhibition of SRC/FAK cue: A novel pathway for the synergistic effect of rosuvastatin on the anti-cancer effect of dasatinib in hepatocellular carcinoma.** Life Sciences 213 (2018) 248–257
40. Hadeer M Abdelaziz, Ahmed O Elzoghby, [Maged W Helmy](#), Magda W Samaha, Jia-You Fang, May S. Freag. **Liquid crystalline assembly for potential combinatorial chemo–herbal drug delivery to lung cancer cells.** International Journal of Nanomedicine 2019;14 499–517
41. Mai M. Helmy, [Maged W. Helmy](#), Mahmoud M. El-Ma. **Upregulation of cystathionine- $\gamma$ -lyase/hydrogen sulfide pathway underlies the celecoxib counteraction of cyclosporine-induced hypertension and renal insult in rats.** Prostaglandins and Other Lipid Mediators 141 (2019) 1–10
42. Dina G. Zayed<sup>1</sup>, Shaker M. Ebrahim, Maged W. Helmy, Sherine N. Khattab, Mohammed Bahey-El-Din, Jia-You Fang, Kadria A. Elkhodairy and Ahmed O. Elzoghby. **Combining hydrophilic chemotherapy and hydrophobic phytotherapy via tumor-targeted albumin-QDs**

- nano-hybrids: covalent coupling and phospholipid complexation approaches.* Journal of Nanobiotechnology, 2019 Jan 19;17(1):7. doi: 10.1186/s12951-019-0445-7.
43. Nayra M Kamel, [Maged W Helmy](#), Elsayeda-Zeinab Abdelfattah, Sherine Nabil Khattab, Doaa Ragab, Magda W Samaha, Jia-You Fang, Ahmed O Elzoghby. **Inhalable dual-targeted hybrid lipid nanocore-protein shell composites for combined delivery of genistein and all-trans retinoic acid to lung cancer cells.** ACS Biomaterials Science & Engineering Publication date 2019/3/6
44. Lobna M Abdel Moneim, [Maged W Helmy](#), Hanan S El-Abhar. **Co-targeting of endothelin-A and vitamin D receptors: a novel strategy to ameliorate cisplatin-induced nephrotoxicity.** Pharmacological Reports. 2019 Apr 25;71(5):917-925. doi: 10.1016/j.pharep.2019.04.018.
45. Mariam Zewail, Noha Nafee, Maged W. Helmy, Nabila Boraie. **Coated nanostructured lipid carriers targeting the joints-An effective and safe approach for the oral management of rheumatoid arthritis.** International Journal of Pharmaceutics 567 (2019) 118447
46. Nayra M Kamel, Maged W Helmy, Magda W Samaha, Doaa Ragab & Ahmed O. Elzoghby. **Multicompartmental lipid-protein nano hybrids for combined tretinoin/herballung cancer therapy.** .Nanomedicine (Lond). 2019 doi: [doi.org/10.2217/nnm-2019-0090](https://doi.org/10.2217/nnm-2019-0090)
47. Mona A. Abdelmoneem, Manar A. Elnaggar, Ruwan S. Hammady, Shaza M. Kamel, Maged W. Helmy, Mohammad A. Abdulkader, Amira Zaky, Jia-You Fang, Kadria A. Elkhodairy, and Ahmed O. Elzoghby. **Dual-Targeted Lactoferrin Shell-Oily Core Nanocapsules for Synergistic Targeted/Herbal Therapy of Hepatocellular Carcinoma.** ACS Appl. Mater. Interfaces 2019, 11, 26731–26744
48. Basma M. Abdelaziz, Maged W. Helmy, Mohamed A. Katary, Mohammad M. Abd-Alhaseeb, Asser I. Ghoneim. **Protective effects of Astragalus kahiricus root extract on ethanol-induced retrograde memory impairments in mice.** J Herbmed Pharmacol. 2019; [8\(4\)](#): 295-301. doi: [10.15171/jhp.2019.43](https://doi.org/10.15171/jhp.2019.43)
49. [Helmy MW](#), Ghoneim AI, Katary MA, Elmahdy RK. **The synergistic anti-proliferative effect of the combination of diosmin and BEZ-235 (dactolisib) on the HCT-116 colorectal cancer cell line occurs through inhibition of the PI3K/Akt/mTOR/NF- $\kappa$ B axis.** Molecular Biology Report. 2020 Mar;47(3):2217-2230. doi: 10.1007/s11033-020-05327-4
50. Omnia M. Ali, Adnan A. Bekhit, Sherine N. Khattab, [Maged W. Helmy](#), Yasser S. Abdel-Ghany, Mohamed Teleb, Ahmed O. Elzoghby. **Synthesis of lactoferrin mesoporous silica nanoparticles for pemetrexed/ellagic acid synergistic breast cancer therapy.** Colloids and Surfaces B: Biointerfaces. Volume 188, April 2020, 110824
51. Hadeer M. Abdelaziz, Ahmed O. Elzoghby, [Maged W. Helmy](#), Elsayeda-Zeinab A. Abdelfattah, Jia-You Fang, Magda W. Samaha, and May S. Freag. **Inhalable Lactoferrin/Chondroitin-Functionalized Monoolein Nanocomposites for Localized Lung Cancer Targeting.** ACS Biomaterials Science & Engineering 2020 6 (2), 1030-1042. DOI: 10.1021/acsbiomaterials.9b01639
52. Ragwa M Farid, Passent M E Gaafar, Heba A Hazzah, [Maged W Helmy](#) & Ossama Y Abdallah. **Chemotherapeutic potential of L-carnosine from stimuli-responsive magnetic nanoparticles against breast cancer model.** Nanomedicine (Lond). 2020 Apr 2. doi: 10.2217/nnm-2019-0428.

53. Noha Nafee, Dina M. Gaber, Ahmed O. Elzoghby, [Maged W. Helmy](#) & Osama Y. Abdallah **Promoted Antitumor Activity of Myricetin against Lung Carcinoma Via Nanoencapsulated Phospholipid Complex in Respirable Microparticles.** *Pharm Res* 37, 82 (2020). <https://doi.org/10.1007/s11095-020-02794-z>
54. Mohamed Gaber; Kholod A. Elhasany; Saly Sabra; [Maged W. Helmy](#); Jia-You Fang; Sherine N. Khattab; Adnan A. Bekhit; Mohamed Teleb; Kadria A. Elkodairy; Ahmed O. Elzoghby. **Co-Administration of Tretinoin Enhances the Anti-Cancer Efficacy of Etoposide via Tumor-Targeted Green Nano-Micelles.** *Colloids and Surfaces B: Biointerfaces* 2020-04-25 , DOI: 10.1016/j.colsurfb.2020.110997
55. Jilan A. Nazeam, Walaa A. AL-Shareef, [Maged W. Helmy](#), Alaadin E. El-Haddad. **Bioassay-guided isolation of potential bioactive constituents from pomegranate agrifood by-product** .*Food Chemistry* 326 (2020) 126993
56. Perihan A.Elzahhar, Shrouk M.Abd El Wahab, Mohamed Elagawany, Hoda Daabees, Ahmed S.F.Belal, Ahmed F.EL-Yazbi, Ali H.Eid, Rana Alaaeddine, Rehab R.Hegazy, Rasha M. Allam, [Maged W.Helmy](#), Bahaa Elgendy, Andrea Angeli, Soad A.El-Hawash, Claudiu T. Supuran. **Expanding the anticancer potential of 1,2,3-triazoles via simultaneously targeting Cyclooxygenase-2, 15-lipoxygenase and tumor-associated carbonic anhydrases.** *European Journal of Medicinal Chemistry*. Volume 200, 15 August 2020, 112439
57. El-Tedawy DM, Abd-Alhaseeb MM, Helmy MW, Ghoneim AI. **Systemic bee venom exerts anti-arthritic and anti-inflammatory properties in a rat model of arthritis.** *Biomed Rep.* 2020;13(4):20. doi:10.3892/br.2020.1327
58. Mona A. Abdelmoneem, Mahmoud M. Abd Elwakil, Sherine N. Khattab, [Maged W. Helmy](#), Adnan A. Bekhit, Mohammad A. Abdulkader, Amira Zaky, Mohamed Teleb, Kadria A. Elkodairy, Fernando Albericio, Ahmed O. Elzoghby. **Lactoferrin-Dual Drug Nanoconjugate: Synergistic Anti-Tumor Efficacy of Docetaxel and the NF- $\kappa$ B inhibitor Celastrol.** *Materials Science and Engineering: C*. August 2020, 111422. doi.org/10.1016/j.msec.2020.111422.
59. Kholod A. Elhasany, Sherine N. Khattab, Adnan A. Bekhit, Doaa M. Ragab, Mohammad A. Abdulkader, Amira Zaky, [Maged W. Helmy](#), Hayam M.A. Ashour, Mohamed Teleb, Nesreen S. Haiba, Ahmed O. Elzoghby. **Combination of magnetic targeting with synergistic inhibition of NF- $\kappa$ B and glutathione via micellar drug nanomedicine enhances its anti-tumor efficacy.** *European Journal of Pharmaceutics and Biopharmaceutics*, 2020, <https://doi.org/10.1016/j.ejpb.2020.08.004>
60. Nasser, F., Moussa, N., [Helmy, M.W.](#) Haroun M.. **Dual targeting of Notch and Wnt/ $\beta$ -catenin pathways: Potential approach in triple-negative breast cancer treatment.** *Naunyn-Schmiedeberg's Arch Pharmacol* (2020). <https://doi.org/10.1007/s00210-020-01988-x>